Canaccord analyst George Gianarikas lowered the firm’s price target on Aspen Aerogels (ASPN) to $5 from $10 and keeps a Buy rating on the shares. The firm said with a solid balance sheet and minimal capital expenditure needs, liquidity is expected to remain healthy. And looking past 2026, they expect a return to healthy levels of EBITDA with material flow through to free cash flow.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ASPN: